Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944423 · ClinicalTrials.gov registry record · Early Phase 1
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
A Early Phase 1 study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 53
- Enrollment target
NCT01944423 is a Early Phase 1 study that has completed, run by University of Texas at Austin. The registered enrollment target is 53 participants.
The verdict
NCT01944423, a Early Phase 1 study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. The investigators hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence greater smoking abstinence rates and decreased panic symptoms after receiving a combined CBT-based treatment for smokers with panic attacks.
Interventions
- DRUG d-cycloserine
- DRUG Pill Placebo
- DRUG Nicotine replacement therapy
- BEHAVIORAL Panic and Smoking Reduction Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01944423
The ClinicalTrials.gov registry entry for NCT01944423 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which d-cycloserine is the first listed.
NCT01944423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01944423 about?
NCT01944423 is a clinical study titled "Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine". The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. The investigators hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence greater smoking abstinence rates ...
What is the current status of trial NCT01944423?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 53 participants. The study started on 2013-10. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01944423?
The interventions under investigation include: d-cycloserine (DRUG), Pill Placebo (DRUG), Nicotine replacement therapy (DRUG), Panic and Smoking Reduction Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01944423?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.